|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk of cardiovascular,cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease(NAFLD)has emerged as a public health problem of epidemic proportions worldwide.Accumulating clinical and epidemiological evidence indicates that NAFLD is not only associated with liver-related morbidity and mortality but also with an increased risk of coronary heart disease(CHD),abnormalities of cardiac function and structure(e.g.,left ventricular dysfunction and hypertrophy,and heart failure),valvular heart disease(e.g.,aortic valve sclerosis)and arrhythmias(e.g.,atrial fibrillation).Experimental evidence suggests that NAFLD itself,especially in its more severe forms,exacerbates systemic/hepatic insulin resistance,causes atherogenic dyslipidemia,and releases a variety of pro-inflammatory,pro-coagulant and pro-fibrogenic mediators that may play important roles in the pathophysiology of cardiac and arrhythmic complications.Collectively,these findings suggest that patients with NAFLD may benefit from more intensive surveillance and early treatment interventions to decrease the risk for CHD and other cardiac/arrhythmic complications.The purpose of this clinical review is to summarize the rapidly expanding body of evidence that supports a strong association between NAFLD and cardiovascular,cardiac and arrhythmic complications,to briefly examine the putative biological mechanisms underlying this association,and to discuss some of the current treatment options that may influence both NAFLD and its related cardiac and arrhythmic complications. | Stefano Ballestri Amedeo Lonardo Stefano Bonapace Christopher D Byrne Paola Loria Giovanni Targher | 2014 | World Journal of Gastroenterology2014，20，7： | 55 |
| 2 | Nonalcoholic fatty liver disease and aging: Epidemiology to management显示文摘Nonalcoholic fatty liver disease(NAFLD) is common in the elderly, in whom it carries a more substantial burden of hepatic(nonalcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma) and extra-hepatic manifestations and complications(cardiovascular disease, extrahepatic neoplasms) than in younger age groups. Therefore, proper identification and management of this condition is a major task for clinical geriatricians and geriatric hepatologists. In this paper, the epidemiology and pathophysiology of this condition are reviewed, and a full discussion of the link between NAFLD and the aspects that are peculiar to elderly individuals is provided; these aspects include frailty, multimorbidity, polypharmacy and dementia. The proper treatment strategy will have to consider the peculiarities of geriatric patients, so a multidisciplinary approach is mandatory. Non-pharmacological treatment(diet and physical exercise) has to be tailored individually considering the physical limitations of most elderly people and the need for an adequate caloric supply. Similarly, the choice of drug treatment must carefully balance the benefits and risks in terms of adverse events and pharmacological interactions in the common context of both multiple health conditions and polypharmacy. In conclusion, further epidemiological and pathophysiological insight is warranted. More accurate understanding of the molecular mechanisms of geriatric NAFLD will help in identifying the most appropriate diagnostic and therapeutic approach for individual elderly patients. | Marco Bertolotti Amedeo Lonardo Chiara Mussi Enrica Baldelli Elisa Pellegrini Stefano Ballestri Dante Romagnoli Paola Loria | 2014 | World Journal of Gastroenterology2014，20，39： | 15 |
| 3 | Fatty liver,carotid disease and gallstones:A study of age-related associations显示文摘AIM: To evaluate carotid intima-media thickening (IMT) and plaques, gallstone disease (GD) and fatty liver (FL) as a function of age. METHODS: In 449 subjects, FL and carotid disease were assessed ultrasonographically. In a subgroup of 65/449 patients with non-alcoholic fatty liver disease (NAFLD), carotid disease, GD and associated factors were determined. RESULTS: FL of unspecified etiology was more common in younger and GD in older individuals. FL subjects had an increased prevalence of IMT and a decreased prevalence of plaques and manifested carotid disease earlier. Plaques were more common in subjects with GD. Age was an independent predictor of carotid disease outcome and FL was a protective factor for plaques. In NAFLD, there was an inverse correlation between body weight and age and the latter independently predicted carotid findings. CONCLUSION: Cardiovascular risk in patients with FL and NAFLD needs to be assessed as a function of age and body weight. | Amedeo Lonardo Silvia Lombardini Federica Scaglioni Stefano Ballestri Anna Maria Verrone Marco Bertolotti Lucia Carulli Dorval Ganazzi Nicola Carulli Paola Loria | 2006 | World Journal of Gastroenterology2006，12，36： | 14 |
| 4 | Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms显示文摘Hepatitis C virus(HCV)infection represents a major health issue worldwide due to its burden of chronic liver disease and extrahepatic manifestations including cardiovascular diseases,which are associated with excess mortality.Analysis of published studies supports the view that HCV infection should be considered a risk factor for the development of carotid atherosclerosis,heart failure and stroke.In contrast,findings from studies addressing coronary artery disease and HCV have yielded conflicting results.Therefore,meta-analytic reviews and prospective studies are warranted.The pathogenic mechanisms connecting HCV infection,chronic liver disease,and atherogenesis are not completely understood.However,it has been hypothesized that HCV may promote atherogenesis and its complications through several direct and indirect biological mechanisms involving HCV colonization and replication within arterial walls,liver steatosis and fibrosis,enhanced and imbalanced secretion of inflammatory cytokines,oxidative stress,endotoxemia,mixed cryoglobulinemia,perturbed cellular and humoral immunity,hyperhomocysteinemia,hypo-adiponectinaemia,insulin resistance,type 2 diabetes and other components of the metabolic syndrome.Understanding these complex mechanisms is of fundamental importance for the development of novel therapeutic approaches to prevent and to treat vascular complications in patients with chronic HCV infection.Currently,it seems that HCV clearance by interferon and ribavirin treatment significantly reduces non-liver-related mortality;moreover,interferon-based treatment appears to decrease the risk of ischemic stroke. | Luigi E Adinolfi Rosa Zampino Luciano Restivo Amedeo Lonardo Barbara Guerrera Aldo Marrone Fabio Nascimbeni Anna Florio Paola Loria | 2014 | World Journal of Gastroenterology2014，20，13： | 6 |
| 5 | Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD显示文摘 | Stefano Ballestri Amedeo Lonardo Dante Romagnoli Lucia Carulli Luisa Losi Christopher P. Day Paola Loria | 2012 | Liver Int2012，，8： | 4 |
| 6 | Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis显示文摘 | Luigi E. Adinolfi Luciano Restivo Rosa Zampino Barbara Guerrera Amedeo Lonardo Laura Ruggiero Francesco Riello Paola Loria Anna Florio | 2012 | Atherosclerosis2012，，2： | 3 |
| 7 | Metabolic alterations and chronic hepatitis C: treatment strategies显示文摘 | Luigi E Adinolfi Luciano Restivo Rosa Zampino Amedeo Lonardo Paola Loria | 2011 | Expert Opinion on Pharmacotherapy2011，，14： | 3 |
| 8 | From NAFLD in clinical practice to answers from guidelines显示文摘 | Fabio Nascimbeni Raluca Pais Stefano Bellentani Christopher Paul Day Vlad Ratziu Paola Loria Amedeo Lonardo | 2013 | Journal of Hepatology2013，，： | 3 |
| 9 | Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis显示文摘 | Luigi E. Adinolfi Luciano Restivo Rosa Zampino Barbara Guerrera Amedeo Lonardo Laura Ruggiero Francesco Riello Paola Loria Anna Florio | 2012 | Atherosclerosis2012，，2： | 2 |
| 10 | Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD显示文摘 | Amedeo Lonardo Silvia Sookoian Michel Chonchol Paola Loria Giovanni Targher | 2013 | Current Pharmaceutical Design2013，，29： | 2 |
| 11 | Potential for statins in the chemoprevention and management of hepatocellular carcinoma显示文摘 | Amedeo Lonardo Paola Loria | 2012 | J Gastroenterol Hepatol2012，，11： | 1 |
| 12 | Metabolic alterations and chronic hepatitis C: treatment strategies显示文摘 | Luigi E Adinolfi Luciano Restivo Rosa Zampino Amedeo Lonardo Paola Loria | 2011 | Expert Opinion on Pharmacotherapy2011，，14： | 1 |
| 13 | Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?显示文摘 | Lucia Carulli Stefano Ballestri Amedeo Lonardo Francesca Lami Enrico Violi Luisa Losi Lisa Bonilauri Anna Maria Verrone Maria Rosaria Odoardi Federica Scaglioni Marco Bertolotti Paola Loria | 2013 | Internal and Emergency Medicine2013，，4： | 1 |
| 14 | Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD)显示文摘 | Federica Scaglioni Mariano Marino Stefania Ciccia Alessia Procaccini M. Busacchi Paola Loria Amedeo Lonardo Marcella Malavolti Nino Carlo Battistini Massimo Pellegrini Francesca Carubbi Stefano Bellentani | 2012 | Clinics and Research in Hepatology and Gastroenterology2012，，： | 1 |
| 15 | From NAFLD in clinical practice to answers from guidelines<!-- Doctopic: Review -->显示文摘 | Fabio Nascimbeni Raluca Pais Stefano Bellentani Christopher Paul Day Vlad Ratziu Paola Loria Amedeo Lonardo | 2013 | Journal of Hepatology2013，，： | 1 |
| 16 | Potential for statins in the chemoprevention and management of hepatocellular carcinoma显示文摘 | Amedeo Lonardo Paola Loria | 2012 | J Gastroenterol Hepatol2012，，11： | 1 |
| 17 | Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease显示文摘 | Giovanni Guaraldi Amedeo Lonardo Stefano Ballestri Stefano Zona Chiara Stentarelli Gabriella Orlando Federica Carli Lucia Carulli Alberto Roverato Paola Loria | 2011 | Archives of Medical Research2011，，8： | 1 |
| 18 | Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates显示文摘 | Paola Loria Amedeo Lonardo Francesca Leonardi Cristina Fontana Lucia Carulli Anna Maria Verrone Andrea Borsatti Marco Bertolotti Fabio Cassani Alberto Bagni Paolo Muratori Dorval Ganazzi Francesco B. Bianchi Nicola Carulli | 2003 | Digestive Diseases and Sciences2003，，11： | 1 |
| 19 | From NAFLD in clinical practice to answers from guidelines显示文摘 | Fabio Nascimbeni Raluca Pais Stefano Bellentani Christopher Paul Day Vlad Ratziu Paola Loria Amedeo Lonardo | 2013 | Journal of Hepatology2013，，4： | 1 |
| 20 | Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease显示文摘 | Amedeo Lonardo Luigi E. Adinolfi Paola Loria Nicola Carulli Giuseppe Ruggiero Christopher P. Day | 2004 | Gastroenterology2004，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员